Recent Updates
Recently added Catalysts
RARE

Ultragenyx Announces Top-Line Results from Phase 3 Study of Ace-ER in GNE Myopathy

Tuesday, August 22, 2017 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Ultragenyx Announces Top-Line Results from Phase 3 Study of Ace-ER in GNE Myopathy

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+43%
120-day peak, hindsight
Typical move
2.9%
average across 6 past catalysts
Cash runway
~13 mo
Low dilution risk
Lead asset
BPS804
Phase 2 · Hypophosphatasia

Full Press Release Details

Ultragenyx Announces Top-Line Results from Phase 3 Study of Ace-ER in GNE Myopathy.
ShareAdd on Google
Tags: RARE Viatris Investor Conferences Healthcare investor conferences healthcare conferences UBS Global Healthcare
Last updated: Aug 22, 2017

Biotech snapshot

Cash runway
$436M liquidity · $32M/mo burn
~13 mo
Low dilution risk
Lead asset
BPS804Phase 2
Hypophosphatasia →

Catalyst track record

+43%
best trade around RARE's most recent catalyst

Peak hindsight return over a 120-day window, across 6 tracked FDA/PDUFA catalysts for RARE.

See every catalyst's timing & PoA →